Learn how AI is transforming predictions of drug-induced liver injury and aiding drug development for safer therapeutics.

Illumina launched the Billion Cell Atlas to train AI on one billion single cells. AstraZeneca, Merck and Lilly are founding ...

N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a ...

The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...

AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of ...

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.

AI Impact explores why AI security has outgrown human oversight, plus pricing gains, health care insight and key AI moves in ...

Cancer immunity and immunotherapy research increasingly recognizes that chronic inflammation is a major driver of tumorigenesis, yet the complex and dynamic ...

Explore the groundbreaking AI genomics platform, Inference, launched by Variant Bio to enhance drug discovery using genetic ...

Organoids have now evolved beyond simple experimental models to become next-generation biological platforms that precisely replicate human organ ...

The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...

Frost & Sullivan is pleased to announce that BostonGene has been recognized for 2025 Global Technology Innovation Leadership in the ...